SpringWorks Therapeutics Inc 2024年度报告

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes x No ¨ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.Yes ¨ No x Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨ Indicate by check mark whether the registrant has submitted electronically; every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files).Yes x No ¨ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filerAccelerated filerNon-accelerated filerSmaller reporting companyEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of theeffectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) bythe registered public accounting firm that prepared or issued its audit report. If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo x The number of outstanding shares of the registrant’s common stock as of February 14, 2025 was 74,935,850. Documents Incorporated by ReferenceThe registrant's definitive proxy statement relating to the annual meeting of shareholders will be filed with the Securities and Exchange Commission within 120 days after the close of the registrant's fiscal year ended December 31, 2024 and is incorporatedby reference in Part III to the extent described herein. Table of Contents SpringWorks TherapeuticsAnnual Report on Form 10-KTable of Contents PART I Item 1.Business4Item 1A.Risk Factors34Item 1B.Unresolved Staff Comments86Item 1C.Cybersecurity86Item 2.Properties87Item 3.Legal Proceedings87Item 4.Mine Safety Disclosures87 PART II Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters andIssuer Purchases of Equity Securities88Item 6.[Reserved]89Item 7.Management’s Discussion and Analysis of Financial Condition and Results ofOperations90Item 7A.Quantitative and Qualitative Disclosures About Market Risk103Item 8.Financial Statements and Supplementary Data105Item 9.Changes in and Disagreements With Accountants on Accounting andFinancial Disclosure132Item 9A.Controls and Procedures132Item 9B.Other Information135Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections135 PART III Item 10.Directors, Executive Officers and Corporate Governance136Item 11.Executive Compensation136Item 12.Security Ownership of Certain Beneficial Owners and Management andRelated Stockholder Matters136Item 13.Certain Relationships and Related Transactions, and Director Independence136 Item 14. PART IV Item 15.Exhibits and Financial Statement Schedules137Item 16.Form 10-K Summary137 1 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements that involverisks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisionsof the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statementsother than statements of historical facts contained in this Annual Report are forward-looking statements.In some cases, these forward-looking statements can be identified by the use of words such as “may”,“will”, “should”, “expects”, “intends”, “plans”, “anticipates”, “believes”, “est